Top entities: LivaNova, Stefano Folli, Franco Poletti, Vladimir Makatsaria, Philips — Saeco.

What category does this event fall under?

Business — classified as executive appointment.

What is the sentiment of coverage?

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business executive appointment

LivaNova appoints Stefano Folli President

Q: When did this event occur?

First reported May 21, 2026; last updated May 21, 2026.

Q: What is the market impact?

General. The appointment of Stefano Folli>>> as President of Cardiopulmonary at LivaNova>>> is viewed positively by the market, as it signals a strategic move to bolster leadership and drive growth in a key business segment.

Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 21, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The appointment of Stefano Folli>>> as President of Cardiopulmonary at LivaNova>>> is viewed positively by the market, as it signals a strategic move to bolster leadership and drive growth in a key business segment. This could lead to increased investor confidence in LivaNova>>>'s future performance and potentially impact its stock price positively.

medical technology healthcare

Event Summary

LivaNova>>>, a medical technology company, announced the appointment of Stefano Folli>>> as the new President of its Cardiopulmonary (CP) business, effective June 1, 2026. Folli will succeed Franco Poletti>>>, who is set to retire on July 31, 2026. Folli will work closely with Poletti to ensure a smooth leadership transition before assuming full responsibility on August 1. In his new role, Folli will oversee the strategic growth of the nearly $800 million CP division, which includes a range of disposables and equipment like the Essenz Perfusion System. Folli brings over three decades of experience, including a 16-year tenure at Philips>>> where he served as Executive Vice President, Global President Ambulatory Monitoring & Diagnostics. He also held leadership positions at Philips — Saeco>>>. LivaNova>>>'s CEO, Vladimir Makatsaria>>>, highlighted Folli's strategic vision and operational excellence as key assets for the company.

Entities Involved

stock

LivaNova

LivaNova appointed Stefano Folli>>> as the new President of its Cardiopulmonary business, which is expected to strengthen the division's strategic growth and innovation. This leadership change is part of the company's ongoing efforts to enhance its market position in medical technology.

Importance 100.0 Sentiment 20.0

per

Stefano Folli

Stefano Folli>>> was appointed President of the Cardiopulmonary business at LivaNova>>>, bringing over three decades of experience in healthcare and medtech to oversee the strategic growth of the nearly $800 million division.

Importance 90.0 Sentiment 30.0

per

Franco Poletti

Franco Poletti>>> is retiring from his role as President of Cardiopulmonary at LivaNova>>>, ensuring a smooth transition of leadership to Stefano Folli>>>.

Importance 50.0 Sentiment 0.0

per

Vladimir Makatsaria

Vladimir Makatsaria>>>, CEO of LivaNova>>>, announced the appointment of Stefano Folli>>> and expressed confidence in his ability to lead the Cardiopulmonary business.

Importance 40.0 Sentiment 10.0

subs

Philips — Saeco

Philips — Saeco>>> is a former employer of Stefano Folli>>>, where he served as Chief Executive Officer, adding to his diverse leadership background.

Importance 10.0 Sentiment 0.0

stock

Philips

Importance 0 Sentiment 0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard